Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLUMBIA-1: Novel Oncology Therapies + Chemotherapy + Bevacizumab in First-line Metastatic MSS-CRC
NCT04068610Phase 2Active, not recruiting
- Sponsor
- MedImmune
- Start
- Sep 2019
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of durvalumab, oleclumab in colorectal cancer (CRC), sponsored by MedImmune. Started Sep 2019; status: active, not recruiting.
02
Drugs
durvalumaboleclumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04068610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068610.